Kala Pharmaceuticals (NASDAQ: KALA)
Kala Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kala Pharmaceuticals Company Info
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
News & Analysis
Why Kala Pharmaceuticals Stock Sank Today
Good news from the FDA translated to bad news for Kala's share price.
Keep Your Eye on These 4 Healthcare Stocks
The growing eye industry is something investors can’t ignore.
How Medical Billing Coverage Spells Success Or Failure For Drugmakers
How important is it for drugmakers to get their new innovations reimbursed by Medicare? Turns out, it can be life or death for their stocks.
Kala Pharmaceuticals Reports Disappointing Q2 Sales
The company finally has a drug product on the market, but it didn't live up to Wall Street's expectations in the second quarter.
Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today
The pharma company announced the pricing of a share offering.
Here's Why Kala Pharmaceuticals Got Crushed on Friday
The tiny pharma stock's future is cloudier than ever.
Valuation
Earnings Transcripts
Kala Pharmaceuticals, Inc. (KALA) Q1 2020 Earnings Call Transcript
KALA earnings call for the period ending March 31, 2020.
Kala Pharmaceuticals, Inc. (KALA) Q2 2019 Earnings Call Transcript
KALA earnings call for the period ending June 30, 2019.
Kala Pharmaceuticals, Inc. (KALA) Q1 2019 Earnings Call Transcript
KALA earnings call for the period ending March 31, 2019.
Kala Pharmaceuticals, Inc. (KALA) Q4 2017 Earnings Conference Call Transcript
KALA earnings call for the period ending December 31, 2017.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.